Clinical Trial

Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics of NTB003 in Healthy Participants

Enrolling by Invitation Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2025 (before its estimated February 23, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a randomized, double-blind, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic characteristics of NTB003 injection in healthy volunteers.
Trial Details
NCT Number NCT07182552
Lead Sponsor Nanjing Chia-tai Tianqing Pharmaceutical
Conditions TED
Enrollment 40 participants
Start Date 2025-06-30
Primary Completion 2026-02-23 (estimated)
Study Completion 2026-03-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-19